Biotechnology News and Research

RSS

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Rituxan's sBLA receives a Complete Response from the FDA

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.

19 Oct 2009

Clemson University receives a $9.3M NIH grant to establish a tissue regeneration center

Clemson University has received a $9.3 million, five-year National Institutes of Health (NIH) grant to establish a Center of Biomedical Research Excellence (COBRE) for Tissue Regeneration. Faculty from the Medical University of South Carolina and the University of South Carolina also will collaborate, providing expertise in medicine and developmental biology.

19 Oct 2009

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Biogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies’ long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.

19 Oct 2009

Update from Cardiome Pharma regarding its tender offer

Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.

19 Oct 2009

Gates Foundation to announce grants to promote agriculture at world food prize symposium

During a "keynote speech" Thursday at the World Food Prize Symposium in Des Moines, Iowa, Bill Gates, cofounder of the Bill & Melinda Gates Foundation, is expected to announce $120 million in grants "to promote dynamic, home-grown, sustainable agriculture in Africa and India,"

19 Oct 2009

Cancer Therapeutics and Nanotherapies sign letter of intent

Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.

19 Oct 2009

New EVestG diagnostic technique aids in quick detection of mental and neurological illnesses

An innovative diagnostic technique invented by a Monash University researcher could dramatically fast-track the detection of mental and neurological illnesses.

19 Oct 2009

CK Life Sciences acquires additional voting shares of WEX Pharmaceuticals

CK Life Sciences Int'l., (Holdings) Inc. ("CKLS") of Hong Kong (Hong Kong Stock Exchange Limited Stock Code 0775) and WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that CKLS has acquired an additional 116,852,062 restricted voting shares of WEX to bring its holding to 133,179,334 restricted voting shares, or 75.25% of the total outstanding restricted voting shares.

19 Oct 2009

Overview of innovative technology for treating ischemic and autoimmune disorders

Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

15 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Baxter International Inc. today reported solid financial results for the third quarter of 2009, and provided its fourth quarter and updated full-year 2009 financial outlook.

From Baxter International Inc. 15 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

BNA Books publishes the 2009 Cumulative Supplement to Pharmaceutical Patent Law

The 2009 Cumulative Supplement to Pharmaceutical Patent Law delivers the latest legal developments in pharmaceutical patent law.

15 Oct 2009

Small biotechnology companies fail to attact new capital, BIO conveyes support for Investment Act of 2009

Small biotechnology companies developing new medical therapies and advanced biofuels need help attracting new capital, as investors have become especially risk averse. The Biotechnology Industry Organization (BIO) today conveyed support for the Small Business Early-Stage Investment Act of 2009, which would create a funding program at the Small Business Administration to stimulate growth in early-stage technology-based companies.

15 Oct 2009

Specific immune system cells linked to susceptibility of younger people to variant CJD

Specific cells within the immune system could help explain why younger people are more susceptible to variant CJD, scientists believe.

15 Oct 2009

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that the last patient in the Phase III clinical trial being conducted by its collaborative partner, Alimera Sciences, for a new treatment for diabetic macular edema (DME) has completed the two-year follow up visit.

15 Oct 2009

Genzyme ranked third on the global list for best employers

Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

15 Oct 2009

BioMedReports.Com releases an exclusive interview with spokesman for Biomagnetics Diagnostics

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has released an exclusive interview with a spokesman for Biomagnetics Diagnostics Corp., the company behind a revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis field testing.

15 Oct 2009

Lonza and Patheon extend exclusivity period; explore transaction options

Lonza Group AG ("Lonza") and the Special Committee of Independent Directors of Patheon Inc. ("Patheon" or the "Company") (TSX:PTI) today announced the extension of the exclusivity period granted to Lonza by Patheon, which had been scheduled to expire today

15 Oct 2009

Biotechnology News and Research

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Rituxan's sBLA receives a Complete Response from the FDA

Clemson University receives a $9.3M NIH grant to establish a tissue regeneration center

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Update from Cardiome Pharma regarding its tender offer

Gates Foundation to announce grants to promote agriculture at world food prize symposium

Cancer Therapeutics and Nanotherapies sign letter of intent

New EVestG diagnostic technique aids in quick detection of mental and neurological illnesses

CK Life Sciences acquires additional voting shares of WEX Pharmaceuticals

Overview of innovative technology for treating ischemic and autoimmune disorders

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

BNA Books publishes the 2009 Cumulative Supplement to Pharmaceutical Patent Law

Small biotechnology companies fail to attact new capital, BIO conveyes support for Investment Act of 2009

Specific immune system cells linked to susceptibility of younger people to variant CJD

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

Genzyme ranked third on the global list for best employers

BioMedReports.Com releases an exclusive interview with spokesman for Biomagnetics Diagnostics

Lonza and Patheon extend exclusivity period; explore transaction options

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News